ASCO Lung Cancer Highlights, Part 9: The MADeIT Study of Predictive Biomarkers for Chemotherapy in Advanced NSCLC by Dr. Edward Garon
ASCO Lung Cancer Highlights, Part 8: The Biomarkers France Study by Dr. Edward Garon
Is there a place for maintenance therapy in extensive stage SCLC?
Drs. Mary Pinder, Nate Pennell, and Jack West discuss whether the finding of improving progression-free survival with maintenance sorafenib for SCLC should change the standard of care for treatment of extensive stage disease.
[powerpress]
How should we integrate new immunotherapies into treatment strategies for lung cancer?
Drs. Jack West, Mary Pinder, and Nate Pennell review various ways in which emerging immunotherapies could be effectively incorporated into our treatment strategies for lung cancer, potentially adding to or replacing current options.
[powerpress]
How do we approach acquired resistance to targeted therapies in lung cancer?
Drs. Jack West, Mary Pinder, and Nate Pennell discuss options for managing acquired resistance to EGFR TKIs and ALK inhibitors in patients with advanced NSCLC and a driver mutation.
[powerpress]
What have we learned from the START trial of immunotherapy in locally advanced NSCLC?
Drs. Nate Pennell, Mary Pinder, and Jack West discuss the START trial of L-BLP-25 (tecemotide) immunotherapy in locally advanced NSCLC.
[powerpress]
Can we target KRAS effectively in advanced NSCLC?
Drs. Mary Pinder, Nate Pennell, and Jack West discuss developments with selumetinib and other MEK inhibitors as a potential target for the 20-25% of NSCLC patients with a KRAS mutation.
[powerpress]
Could BRAF be a new target in NSCLC?
Drs. Nate Pennell, Mary Pinder, and Jack West discuss an encouraging study of dabrafenib, a BRAF inhibitor, for the limited number of NSCLC patients with a BRAF V600E mutation.
[powerpress]